OpenAI Foundation’s $1B grants & Meta child-safety verdict fallout - News (Mar 25, 2026)

We’ll start with artificial intelligence—and a big pledge that’s raising just as many questions as it answers. The OpenAI Foundation, the nonprofit that controls OpenAI and ChatGPT, says it plans to distribute one billion dollars in grants over the next year. The focus: life sciences and health research, plus programs meant to reduce AI’s downsides—things like job disruption, broader economic fallout, and mental-health impacts, especially for children. Why this is interesting is the context. OpenAI began as a nonprofit, then pivoted toward a for-profit structure in 2019. Public filings had shown nonprofit spending and grantmaking dropping sharply, and that’s drawn scrutiny as OpenAI’s valuation and influence surged. A recent regulatory agreement kept the nonprofit board in charge of the for-profit business—while making it easier for investors and the company to profit—so this new philanthropic push will be watched closely as a signal of whether public-benefit promises translate into real-world funding. The foundation says it’s rebuilding, with new leadership roles and an advisory effort that pushed for more community input.

Staying on tech’s real-world impact—one of the biggest legal stories in the U.S. right now: a New Mexico jury found Meta’s platforms harmful to children’s mental health and safety, imposing a 375 million dollar penalty after a lengthy trial. The state argued Meta misled the public about safety and prioritized growth and engagement over protections, including against sexual exploitation and other harms linked to addictive design choices. Jurors sided with the state under consumer protection law, citing thousands of violations, and calling some conduct unconscionable toward children. Meta says it will appeal and argues it invests heavily in safety, while also pointing to how hard it is to police bad actors at scale. Why it matters: this is being treated as a first major verdict in a wave of child-safety cases. More lawsuits are lined up—from a key case in Los Angeles to broader actions by school districts. The bigger question is whether U.S. courts will effectively force changes that lawmakers haven’t, and whether legal shields often cited by platforms will hold up under growing pressure.

Now, a debate that keeps resurfacing as AI accelerates: what counts as “artificial general intelligence,” or AGI. Nvidia CEO Jensen Huang said he believes AGI has already been achieved—by defining it as AI’s ability to build and run a billion-dollar business, possibly through a viral product. That definition is… not universally shared. Critics point out that a fast-scaling app is not the same as sustained, institution-level competence—managing complexity, strategy, compliance, and long-term execution. Huang also acknowledged a key reality check: AI isn’t close to replicating the deep engineering needed to build a company like Nvidia, and he expects Nvidia’s software workforce to grow, not shrink. Still, the comment is consequential because it feeds a powerful narrative: if “AGI is here,” the rush to expand AI infrastructure feels even more urgent—which happens to align with Nvidia’s role supplying the chips powering that buildout.

And speaking of chips, there’s a notable bet on a possible long-term challenger to today’s chipmaking bottlenecks. A Norway-based semiconductor equipment startup called Lace, backed in part by Microsoft’s investment arm, raised 40 million dollars to pursue a new lithography approach. In plain terms: lithography is how chipmakers print the tiny patterns that become transistors. The leading edge today relies heavily on ASML’s light-based tools. Lace says it can use a helium atom beam instead—potentially allowing far smaller features than current methods. That’s a bold claim, and the timeline alone tells you how hard this is: the company is aiming for a test tool in a pilot fabrication setting around 2029. Why it’s interesting: investors and governments are hunting for alternatives in a world where chip supply chains are strategic assets. Even if this doesn’t replace today’s dominant tools soon, it signals renewed appetite for moonshot hardware—because AI demand keeps pushing the limits of what chips can do.

Let’s shift to space, where NASA is clearly leaning into long-duration presence, not just flags-and-footprints. The agency unveiled an ambitious strategy to build a moon base with an estimated price tag around 20 billion dollars. NASA’s message was straightforward: the goal isn’t a brief visit—it’s staying. The significance here is less about one outpost and more about what it enables: continuous science, real infrastructure testing, and a staging ground for deeper missions. But it also raises immediate questions—who pays, how schedules hold, and how NASA coordinates with industry and international partners without the plan becoming an unfunded wish list.

NASA also approved development of another attention-grabber: the Skyfall mission, launching in 2028, designed to deliver three small helicopters to Mars. These won’t just be stunts—they’re intended as practical scouts for future human exploration, checking landing hazards and mapping underground water-ice. The other headline inside this mission is the ride: Skyfall would travel on what NASA calls the first nuclear-powered interplanetary spacecraft, using a reactor-based system to drive electric propulsion. Beyond the immediate mission goals, NASA is trying to establish the track record—and regulatory precedents—needed to make nuclear-powered deep-space travel a normal option rather than a rare exception.

Now to public health, with a rollout that could change prevention patterns for many people. Nigeria has begun deploying a long-acting injectable HIV prevention drug, lenacapavir. The injection is taken once every six months, which officials say could improve adherence and privacy for people who struggle with daily pills—especially among key and vulnerable populations. An initial supply of tens of thousands of doses is being used to start the program in several states plus the Federal Capital Territory. Officials also emphasized important limits: it’s not recommended for pregnant women due to limited evidence, and it doesn’t protect against other sexually transmitted infections. Why this matters is momentum—Nigeria is aiming to push new infections down faster on the path to making HIV/AIDS a far smaller public health threat by 2030.

In biomedical research, there’s a promising step toward making a futuristic therapy feel more manufacturable. Researchers at Xi’an Jiaotong-Liverpool University reported a nanoparticle-based platform aimed at streamlining the production of engineered exosomes—tiny particles released by cells that are being explored as treatments. Exosomes attract attention because they can deliver biological signals or medicines without some of the risks associated with living cell therapies. The big barrier has been scaling: getting consistent output, loading therapeutic cargo, isolating the final product, and preserving it for storage. The new approach claims it can simplify those steps and improve stability, with encouraging results across multiple disease models. It’s early, but the “so what” is clear: if therapies are easier to manufacture reliably, they’re more likely to make it from the lab into clinics—and eventually, into real healthcare systems.

Now to geopolitics, where the pace and scope of conflict remains volatile. As the Iran war entered its fourth week, President Trump declared the conflict “won” and floated the idea of effective regime change. Iranian officials pushed back, rejecting claims that meaningful talks are underway and warning the U.S. against any ground invasion. The region is showing signs of widening pressure. Iran’s Revolutionary Guards claimed missile attacks on Israel and on U.S.-hosted bases in Kuwait, Jordan, and Bahrain. The UAE reported intercepting drones, and Israel said it struck Iranian naval weapons infrastructure, including sites linked to cruise-missile production and submarine manufacturing. Meanwhile, Iraq accused an airstrike near Baghdad of killing seven service members at a military clinic—calling it a violation of international law and warning it may respond. That’s the kind of flashpoint that can pull more actors in. Markets, for their part, rallied and oil dipped on signals of progress—despite Iran’s denials—while the Pentagon announced new framework arrangements with major defense firms to speed munitions production. That combination suggests officials are preparing for the possibility that this doesn’t end quickly.

And one more closely watched development in the region: Israel says it has approved allocating land at Jerusalem’s Allenby Complex to build a permanent U.S. Embassy. Israeli leaders framed it as a long-term symbol of U.S. commitment to Jerusalem as Israel’s capital, rooted in the earlier decision to relocate the embassy. Why this stays sensitive is that physical permanence carries political weight. It reinforces a diplomatic reality for some, and a provocation for others—at a time when the region is already under enormous strain.